MX2015016875A - Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. - Google Patents
Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos.Info
- Publication number
- MX2015016875A MX2015016875A MX2015016875A MX2015016875A MX2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- glp
- peptides
- side chains
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
Abstract
La presente invención se relaciona con derivados de péptidos similares a GLP-1 que son análogos extendidos C-terminalmente de GLP-1 nativo. Los derivados comprenden dos cadenas laterales, una en una posición que corresponde a la posición 42, y una posición que corresponde a la posición 18, 23, 27, 31, 36 ó 38, en donde ambas posiciones son cuando se comparan con GLP-1(7-37). Las cadenas laterales comprenden el radical de prolongación diácido C19, C20 o C22 y opcionalmente un enlazador. La invención también se relaciona con productos intermediarios en la forma de nuevos análogos de GLP-1 incorporados en los derivados de la invención, así como las composiciones farmacéuticas y usos médicos de los derivados. Los derivados tienen viudas medias muy largas, mientras que mantienen una potencia satisfactoria, lo que los hace potencialmente apropiados para la administración una vez al mes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13175094 | 2013-07-04 | ||
US201361845646P | 2013-07-12 | 2013-07-12 | |
PCT/EP2014/064033 WO2015000942A1 (en) | 2013-07-04 | 2014-07-02 | Derivatives of glp-1 like peptides, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015016875A true MX2015016875A (es) | 2016-04-07 |
Family
ID=48703344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015016875A MX2015016875A (es) | 2013-07-04 | 2014-07-02 | Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US9498534B2 (es) |
EP (1) | EP3016975B1 (es) |
JP (2) | JP6139712B2 (es) |
KR (1) | KR20160029079A (es) |
CN (1) | CN105377884B (es) |
AR (1) | AR096789A1 (es) |
AU (1) | AU2014286234A1 (es) |
BR (1) | BR112015032875A2 (es) |
CA (1) | CA2916311A1 (es) |
MX (1) | MX2015016875A (es) |
WO (1) | WO2015000942A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015030948A2 (pt) | 2013-06-20 | 2017-09-19 | Novo Nordisk As | Derivados de glp-1 e usos dos mesmos |
CA2916311A1 (en) * | 2013-07-04 | 2015-01-08 | Novo Nordisk A/S | Derivatives of glp-1 like peptides, and uses thereof |
EP3226906B1 (en) | 2014-11-27 | 2019-06-12 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
US10392428B2 (en) | 2014-12-17 | 2019-08-27 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
WO2017112889A1 (en) | 2015-12-23 | 2017-06-29 | The Johns Hopkins University | Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions |
EP3423481B1 (en) | 2016-03-03 | 2020-10-07 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
JP7076442B2 (ja) | 2016-11-07 | 2022-05-27 | ノヴォ ノルディスク アー/エス | Peg化合物のdchbs活性エステル及びその使用 |
WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
CN108976147B (zh) * | 2017-05-31 | 2021-02-12 | 首都医科大学 | 氨基正己酰氨基甲环酰氨基正己酰碱性氨基酸,其合成,活性和应用 |
CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
US11130794B2 (en) | 2017-07-19 | 2021-09-28 | Novo Nordisk A/S | Bifunctional compounds |
HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
US11339111B2 (en) * | 2017-11-30 | 2022-05-24 | Societe Des Produits Nestle S.A. | Polyketide compound and derivatives thereof for use in the prevention and treatment of a neurological disorder |
EP4364751A3 (en) | 2018-04-05 | 2024-06-26 | Sun Pharmaceutical Industries Limited | Novel glp-1 analogues |
CN113214381B (zh) * | 2018-04-19 | 2024-01-19 | 杭州先为达生物科技股份有限公司 | 酰化的glp-1衍生物 |
CN110386974B (zh) * | 2018-04-19 | 2022-12-09 | 杭州先为达生物科技有限公司 | Glp-1衍生物及其治疗用途 |
WO2019200594A1 (zh) | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
JP6984753B2 (ja) * | 2018-07-12 | 2021-12-22 | 三菱電機株式会社 | 半導体装置 |
CN113597434B (zh) | 2019-12-31 | 2022-07-01 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
US20230082544A1 (en) * | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
CN115925995A (zh) | 2020-09-30 | 2023-04-07 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
ATE466027T1 (de) * | 1998-02-27 | 2010-05-15 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
RU2001128068A (ru) | 1999-03-17 | 2004-02-20 | Ново Нордиск А/С (DK) | Способ ацилирования пептидов и новые ацилирующие агенты |
EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
WO2001035988A1 (en) * | 1999-11-12 | 2001-05-25 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
GB0020551D0 (en) | 2000-08-22 | 2000-10-11 | Birkett David | Sprinkler system |
SI1605897T1 (sl) | 2003-03-19 | 2012-11-30 | Lilly Co Eli | Polietilen glikol povezane GLP spojine |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
PL1881850T3 (pl) | 2005-05-13 | 2011-03-31 | Lilly Co Eli | Pegylowane związki GLP-1 |
JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー/エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
CN102333788A (zh) | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
PL2513140T3 (pl) * | 2009-12-16 | 2016-04-29 | Novo Nordisk As | Podwójnie acylowane pochodne glp-1 |
US9708383B2 (en) | 2010-11-09 | 2017-07-18 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
HUE031405T2 (en) | 2011-04-12 | 2017-07-28 | Novo Nordisk As | Double-acylated GLP-1 derivatives |
CA2916311A1 (en) * | 2013-07-04 | 2015-01-08 | Novo Nordisk A/S | Derivatives of glp-1 like peptides, and uses thereof |
-
2014
- 2014-07-02 CA CA2916311A patent/CA2916311A1/en not_active Withdrawn
- 2014-07-02 AU AU2014286234A patent/AU2014286234A1/en not_active Abandoned
- 2014-07-02 BR BR112015032875A patent/BR112015032875A2/pt not_active Application Discontinuation
- 2014-07-02 KR KR1020167002151A patent/KR20160029079A/ko not_active Application Discontinuation
- 2014-07-02 EP EP14734816.3A patent/EP3016975B1/en active Active
- 2014-07-02 US US14/322,077 patent/US9498534B2/en active Active
- 2014-07-02 JP JP2015563070A patent/JP6139712B2/ja active Active
- 2014-07-02 AR ARP140102467A patent/AR096789A1/es unknown
- 2014-07-02 CN CN201480038380.6A patent/CN105377884B/zh active Active
- 2014-07-02 WO PCT/EP2014/064033 patent/WO2015000942A1/en active Application Filing
- 2014-07-02 MX MX2015016875A patent/MX2015016875A/es unknown
-
2016
- 2016-09-28 US US15/278,501 patent/US10010614B2/en active Active
-
2017
- 2017-02-09 JP JP2017022249A patent/JP6687557B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN105377884B (zh) | 2021-07-20 |
US20150011462A1 (en) | 2015-01-08 |
JP6139712B2 (ja) | 2017-05-31 |
AR096789A1 (es) | 2016-02-03 |
JP2016528163A (ja) | 2016-09-15 |
KR20160029079A (ko) | 2016-03-14 |
EP3016975B1 (en) | 2019-01-16 |
US10010614B2 (en) | 2018-07-03 |
US9498534B2 (en) | 2016-11-22 |
CN105377884A (zh) | 2016-03-02 |
AU2014286234A1 (en) | 2015-12-17 |
WO2015000942A1 (en) | 2015-01-08 |
US20170007707A1 (en) | 2017-01-12 |
JP2017105819A (ja) | 2017-06-15 |
CA2916311A1 (en) | 2015-01-08 |
BR112015032875A2 (pt) | 2017-11-07 |
EP3016975A1 (en) | 2016-05-11 |
JP6687557B2 (ja) | 2020-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015016875A (es) | Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. | |
MX2015016564A (es) | Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos. | |
PH12019501056A1 (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
PH12014501924A1 (en) | Xten conjugate compositions and methods of making same | |
NZ739250A (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
CY1118735T1 (el) | Παραγωγα βενζιμιδαζολο-προλινης | |
MY181181A (en) | Fgf21 derivatives and uses thereof | |
MX2018010247A (es) | Nuevos conjugados de amanitina. | |
WO2011075393A3 (en) | Glucagon/glp-1 receptor co-agonists | |
MX369818B (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
MX2017008215A (es) | Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina. | |
MX2020009857A (es) | Conjugados de interleucina-2 (il-2). | |
MA40030A (fr) | Conjugués peptide-médicament | |
NZ623294A (en) | Stabilized alpha-galactosidase and uses thereof | |
PH12015502755A1 (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
PH12017501280B1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
PH12018501351A1 (en) | Cortistatin analogs and uses thereof | |
PH12020550105A1 (en) | Long-acting conjugates of glp-2 derivatives | |
MX2022006737A (es) | Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados. | |
PH12017501205A1 (en) | Glucagon derivatives | |
EP3888647A4 (en) | EZH1/2 DUAL INHIBITOR CONTAINING PHARMACEUTICAL COMPOSITION FOR USE AS COMBINATION MEDICINAL PRODUCT | |
MX2021003908A (es) | Polipeptidos de accion prolongada y metodos para su produccion y administracion. | |
MX2015006997A (es) | Composicion farmaceutica. |